POSITIVE Study -Implementing Well-Being in Psoriasis Care

Update from the Positive Study Study 2024

Experts Recommend Implementing Well Being in Psoriatic Disease Management

At the IFPA Conference 2024, interim Week 52 results from the POSITIVE clinical study were presented, highlighting the benefits of a novel treatment in patients with moderate to severe psoriasis. The study demonstrated significant improvements in both physical symptoms and overall wellbeing for participants. This pioneering research sheds light on the psychosocial burden of psoriasis and its profound impact on patients' lives, particularly in relation to sensitive areas and high-burden symptoms. Additionally, it shows how the treatment can enhance patients' daily activities, offering benefits that extend beyond symptom relief.

Psoriasis is a common and widespread skin condition, affecting approximately 60 million people worldwide. Studies reveal that nearly 77% of individuals with psoriasis report a negative impact on their daily lives, including personal, social, and work-related activities, as well as their overall sense of wellbeing. This underscores the importance of effective treatments that address both the physical and emotional challenges associated with the disease.

Psoriasis affects around 60 million people worldwide. It not only causes physical discomfort but also takes a toll on people's mental and emotional well-being. Many patients report that psoriasis interferes with their everyday activities, including personal, social, and work life. It also affects the well-being of their families and can even impact physicians' satisfaction.

Read More on the Review Article ; Expert Articles on Wellbeing in Psoriasis Protocols

The POSITIVE study is the first research in dermatology to focus on patients' overall well-being as the most important measure. To do this, they used a questionnaire called the WHO-5, which asks patients about their mental and emotional health in relation to their chronic skin condition. This study goes beyond just looking at the severity of psoriasis. It aims to understand how psoriasis affects a person's whole life and their well-being. The results of this study could lead to new ways for dermatologists to assess and improve their patients' well-being, by taking a more personal and holistic approach to their care.

Almirall – a company focused on skin health leading the first research on focus on patients' well being POSITIVE study protocol. The clinical trial represents the first dermatological research which assesses patient well-being as a primary endpoint.

About the POSITIVE Study

The POSITIVE study uses the 5item World Health Organization Wellbeing Index, WHO-5, a widely used questionnaire that assesses health-related subjective psychological wellbeing in a variety of chronic diseases. Following the holistic approach, the POSITIVE study will also use innovative secondary endpoints, the FamilyPso questionnaire to evaluate the impact of the disease on the family environment, and on Physician wellbeing, using the Physician’s Satisfaction Score.